RedHill Biopharma (Israel) Valuation Overview

RDHL -- Israel Stock  

ILS 252.70  1.10  0.44%

RedHill Biopharma holds recent Real Value of S228.9 per share. The prevailing price of the company is S252.7. At this time the company appears to be over valued. Macroaxis determines value of RedHill Biopharma from analyzing the company fundamentals such as Price to Sales of 85.02X, Current Valuation of 640M and Return On Equity of (112.59)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Horizon     30 Days    Login   to change
RedHill Biopharma Ltd is rated fifth in beta category among related companies. It is rated fourth in price to sales category among related companies fabricating about  566.80  of Price to Sales per Beta.

Current Market Valuation

RedHill Biopharma Valuation Boundaries

Over Valued
December 18, 2018
252.70
Market Value
218.73
Downside
228.90
Real Value
Target Odds
  
277.97
Upside
RedHill Biopharma is not too risky asset. Calculation of real value of RedHill Biopharma is based on 2 months time horizon. Increasing RedHill Biopharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Additionally take a look at Your Equity Center. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Search macroaxis.com